IRADIMED CORP
No SEC Form 4 filings for $IRMD in the last 30 days.
See all $IRMD insider activity →Iradimed Corporation (IRMD) will release its Q3 2026 financial results on Oct. 30 before market open. A conference call is scheduled for 11 a.m. ET to discuss results. IRMD specializes in MRI-compatible medical devices, including IV infusion pumps and patient monitoring systems.
ALLEN MONTY K sold 1,419 shares of IRADIMED CORP (IRMD) at an average of $86.41 ($86.35–$86.44, $0.12M total) across 2 trades on 2026-09-03.
IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IRMD (IRADIMED CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IRMD coverage spans earnings, insider activity and financial news.
The earnings announcement is likely to generate heightened volatility around the release, with the market pricing in expectations and any surprise guidance.
The insider sale represents a modest reduction in holdings by a director, which may signal slight downside pressure.
The earnings call discloses a 3870 pump production ramp, margin compression from start-up inefficiencies, and updated Q3 and full-year guidance.
Routine annual meeting voting results; no new financial guidance, deal, or enforcement action disclosed.
The insider sale may create modest selling pressure.
AlphAI scores every news story that mentions IRMD with an AI model for sentiment and relevance, and aggregates insider trades from IRADIMED CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Iradimed Corporation (IRMD) will release its Q3 2026 financial results on Oct. 30 before market open. A conference call is scheduled for 11 a.m. ET to discuss results. IRMD specializes in MRI-compatible medical devices, including IV infusion pumps and patient monitoring systems.
1 min readALLEN MONTY K sold 1,419 shares of IRADIMED CORP (IRMD) at an average of $86.41 ($86.35–$86.44, $0.12M total) across 2 trades on 2026-09-03.
1 min readIRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.
7 min readIRADIMED CORP (IRMD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. irmd-20260624 0001325618 FALSE 0001325618 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Date of report (Date of earliest event reported): June 24, 2026 IRADIMED CORPORATIO
2 min readScharen-Guivel Hilda Frederique sold 3,000 shares of IRADIMED CORP (IRMD) at $95.00 ($0.28M total) across 2 trades on 2026-06-04.
1 min readIradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.
4 min readSusi Roger E. (CEO, President, Chairman) sold 7,500 indirectly-held shares of IRADIMED CORP (IRMD) at an average of $92.14 ($91.81–$92.93, $0.69M total) across 4 trades over 2026-05-26 to 2026-05-27 under a Rule 10b5-1 trading plan.
2 min readIradimed Corp (NASDAQ: IRMD) has received "Buy" ratings from all three analysts covering the stock, with a median one-year target price suggesting a nearly 34% upside. This positive outlook is driven by the company's unique position as the sole provider of non-magnetic MRI-compatible IV infusion pumps and patient monitoring systems, along with its product growth and potential for international expansion. Freedom Broker initiated coverage with a Buy rating and a $116 price target, highlighting Iradimed's profitability and specialized product portfolio.
3 min readIradimed Co (IRMD) stock has reached an all-time high of $98.24, close to its 52-week high of $98.44, reflecting robust growth over the past year. The company has a market capitalization of $1.25 billion and an 80.67% increase over the past year, with a 68.49% gain in the last six months. InvestingPro's analysis suggests the stock might be overvalued with a P/E ratio of 58.94.
2 min readiRadimed Corporation (NASDAQ:IRMD) announced a special dividend of $0.50 per share, payable on December 30th to shareholders of record on December 17th, with the ex-dividend date also on December 17th. The dividend is covered by earnings, with a payout ratio around 34% and expected EPS of $2.00 next year. Shares recently traded at $95.48 after beating Q last EPS estimates, and Wall Street maintains a "Moderate Buy" rating with an average price target of $87.33.
2 min read
